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Abstract We have found that chitosan, a polysaccharide
present in fungal cell walls, is able to activate macrophages for
enhanced mobilization of arachidonic acid in a dose- and time-
dependent manner. Studies aimed at identifying the intracellular
effector(s) implicated in chitosan-induced arachidonate release
revealed the involvement of the cytosolic Group IV phospholipase
A2 (PLA2), as judged by the inhibitory effect of methyl
arachidonoyl fluorophosphonate but not of bromoenol lactone.
Interestingly, priming of the macrophages with lipopolysaccha-
ride renders the cells more sensitive to a subsequent stimulation
with chitosan, and this enhancement is totally blocked by the
secretory PLA2 inhibitor 3-(3-acetamide)-1-benzyl-2-ethylindo-
lyl-5-oxy-propanesulfonic acid (LY311727). Collectively, the
results of this work establish chitosan as a novel macrophage-
activating factor that elicits AA mobilization in P388D1
macrophages by a mechanism involving the participation of two
distinct phospholipases A2.
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1. Introduction
Chitosan, a polysaccharide comprising copolymers of glu-
cosamine and N-acetyl-glucosamine, is naturally present as an
essential component of fungal cell walls [1]. It can be obtained
by partial deacetylation of chitin (poly N-acetyl-D-glucos-
amine) from crustacean shells. Naturally chitosan is formed
by the action of chitin deacetylases, enzymes that have been
involved either in the formation of the cell wall or in the
deacetylation of chitin oligosaccharides following the action
of an endochitinase on cell walls during autolysis. The forma-
tion of chitosan by chitin deacetylases has also been proposed
to play a role in plant^pathogen interactions [2].
As chitin and chitosan are essential components of fungal
cell walls, both have been the targets of antifungal drugs [3].
Because some of their derivatives are essentially non-toxic,
biodegradable and biocompatible, prostheses produced from
chitin derivatives have been developed [1]. Chitin and chitosan
have been observed to accelerate wound healing properties
and the attainment of an attractive skin surface. It has been
suggested that the mechanism by which chitin and chitosan
act at a wound site involves activation of neutrophils and
macrophages [4]. Histological ¢ndings suggest that these com-
pounds stimulate the migration of polymorphonuclear and
mononuclear cells, and accelerate the reformation of connec-
tive tissue and angiogenesis [5].
Some chitin/chitosan derivatives have been shown to up-
regulate the production of tumor necrosis factor, interleu-
kin-1 and colony-stimulating factor by macrophages and to
induce immunologic adjuvant e¡ects [1,6^8]. Therefore, it was
of interest to examine the capacity of chitosan to mediate
macrophage activation through the release of arachidonic
acid (AA). The results reported here demonstrate that chito-
san can act as a macrophage activator through the mobiliza-
tion of AA and have explored the molecular e¡ectors involved
in this event.
2. Materials and methods
Low molecular weight (LMW) chitosan (molecular weight distribu-
tion 0.5^15 kDa), having a degree of deacetylation of at least 85%,
was obtained from Aldrich (Milwaukee, WI, USA). It was solubilized
in 1% acetic acid, centrifuged to remove insoluble material and puri-
¢ed by precipitation at alkaline pH by the addition of 1 M NaOH
until a pHs 9 was reached. The pellet was centrifuged at 5000 rpm
for 10 min and washed several times with water. Three cycles of
solubilization at acidic pH in 1% acetic acid and precipitation at
alkaline pH were performed in order to remove any contaminating
material from the commercial samples of LMW chitosan. After the
third precipitation at alkaline pH, the pellet was washed with water
until neutral pH was reached. The neutralized chitosan preparation
was then washed several times with ethanol, dried and stored at 4‡C.
Stock solutions of chitosan were prepared in 0.1 M HCl and diluted
with serum-free medium to the appropriate concentration for the ex-
periments.
P388D1 cells (MAB clone) [9,10] were maintained at 37‡C in a
humidi¢ed atmosphere at 90% air and 10% CO2 in Iscove’s modi¢ed
Dulbecco’s medium supplemented with 10% fetal bovine serum,
100 U/ml penicillin and 100 Wg/ml streptomycin. P388D1 cells were
plated at 106 per well, allowed to adhere overnight and used for
experiments the following day. All experiments were conducted in
serum-free Iscove’s modi¢ed Dulbecco’s medium. Radiolabeling of
the P388D1 cells with [3H]AA (speci¢c activity 100 Ci/mmol; New
England Nuclear, Boston, MA, USA) was achieved by including
0.5 WCi/ml [3H]AA during the overnight adherence period (20 h).
Labeled AA that had not been incorporated into cellular lipids was
removed by washing the cells four times with serum-free medium
containing 0.5 mg/ml albumin.
For the [3H]AA release measurements, the cells were placed in
serum-free medium for 30 min before the addition of chitosan for
di¡erent periods of time in the presence of 0.5 mg/ml bovine serum
albumin. The supernatants were removed, cleared of detached cells by
centrifugation and assayed for radioactivity by liquid scintillation
counting. When inhibitors were used, they were added to the cells
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30 min prior to the addition of the stimulus. The sPLA2 (phospholi-
pase A2) inhibitor LY311727 was a generous gift from Dr. Edward
Mihelich (Lilly Research laboratories, Indianapolis, IN, USA). The
cellular PLA2 (cPLA2) inhibitor methyl arachidonyl £uorophospho-
nate (MAFP) was purchased from Biomol (Plymouth Meeting, PA,
USA).
3. Results
We began the current study by determining whether LMW
chitosan was able to cause the extracellular release of AA
from murine P388D1 macrophages. To this end, cells labeled
with [3H]AA were exposed to di¡erent concentrations of chi-
tosan for various periods of time. As shown in Fig. 1, chito-
san induced AA mobilization in a dose- (Fig. 1A) and time-
(Fig. 1B) dependent manner. No AA was released when the
concentration of chitosan was below 0.01% (w/v) and the
plateau was reached at 0.05% (w/v) (Fig. 1A). AA release
proceeded linearly from 5 to 30 min, after which it began to
plateau (Fig. 1B). Interestingly, when the cells were ¢rst
primed with bacterial lipopolysaccharide (LPS) for 1 h and
then exposed to chitosan, the AA release response was mark-
edly enhanced. This is essentially the same phenomenon that
we have previously documented with platelet-activating factor
(PAF) as a triggering agent for AA release [11^14].
Our previous investigations into the molecular mechanisms
of PAF receptor-mediated AA mobilization have highlighted
the involvement of two distinct Ca2-dependent PLA2 en-
zymes in this process, namely the Group IV cytosolic PLA2
and the Group V secretory PLA2 [13^16]. A direct approach
to study the putative involvement of these PLA2s in chitosan-
induced AA mobilization is the use of selective inhibitors of
each of these enzymes. Involvement of cPLA2 was assessed
using MAFP, an irreversible inhibitor of cPLA2 that has no
e¡ect on sPLA2s and other enzymes that could be involved in
AA mobilization (arachidonoyl-CoA synthetase, lysophospha-
tidylcholine:arachidonoyl-CoA acyl transferase or CoA-inde-
pendent transacylases) [17]. More than 70% of the AA release
induced by 0.06% (w/v) LMW chitosan was blocked by
MAFP (25 WM) in both the unprimed and the LPS-primed
cells (Fig. 2), suggesting the involvement of cPLA2 in chito-
san-induced macrophage activation.
MAFP has been found to also inhibit another cPLA2, the
Group VI Ca2-independent PLA2 or iPLA2 [17]. Therefore,
at least part of the MAFP-sensitive AA mobilization could be
mediated by the iPLA2 in addition to the cPLA2. Group VI
iPLA2 is potently and irreversibly inhibited by the mecha-
nism-based inhibitor bromoenol lactone (BEL), a compound
that manifests over a 1000-fold selectivity for inhibition of the
iPLA2 versus the Ca2-dependent PLA2s [18]. BEL at concen-
trations that completely inhibit the iPLA2 from macrophage
cell homogenates (5^25 WM) [19] had no measurable inhibi-
tory e¡ect on chitosan-induced AA release from either un-
primed or LPS-primed cells (data not shown), thus ruling
Fig. 1. Chitosan-stimulated [3H]AA mobilization in P388D1 macro-
phages. A: Dose response of chitosan activation. The cells were ex-
posed to either chitosan alone for 1 h (open circles) or to 100 ng/ml
LPS for 1 h followed by chitosan for 1 h (closed circles); B: Time-
course of [3H]AA release by 0.06% (w/v) chitosan alone (open
circles) or by 100 ng/ml LPS plus 0.06% chitosan (closed circles).
Fig. 2. cPLA2 involvement in chitosan stimulation. E¡ect of MAFP
on chitosan- or LPS/chitosan-induced AA release. [3H]AA-labeled
cells were treated for 1 h with (+) or without (3) 100 ng/ml LPS.
Afterwards, the cells were incubated for 30 min without (3) or with
(+) 25 WM MAFP as indicated. Subsequently, the cells were either
untreated (3) or treated (+) with 0.06% (w/v) chitosan as indicated,
and AA release was determined after 1 h.
Fig. 3. sPLA2 involvement in chitosan stimulation. E¡ect of
LY311727 on chitosan- or LPS/chitosan-induced AA release.
[3H]AA-labeled cells were treated for 1 h with (+) or without (3)
100 ng/ml LPS. Afterwards, the cells were incubated for 30 min
without (3) or with (+) 25 WM LY311727 as indicated. Subse-
quently, the cells were either untreated (3) or treated (+) with
0.06% w/v chitosan as indicated, and AA release was determined
after 1 h.
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out a role for the iPLA2 in this process. In turn, these results
indicate that the MAFP e¡ects described above are all attrib-
utable to the inhibition of the cPLA2.
Involvement of the sPLA2 in chitosan-induced AA release
was assessed by using the indole derivative LY311727, a po-
tent and selective sPLA2 inhibitor [18]. LY311727 markedly
decreased the extracellular release of [3H]AA from LPS-
treated cells (Fig. 3), which is again reminiscent of our pre-
vious results suggesting the involvement of this enzyme in AA
release from LPS-primed P388D1 macrophages stimulated
with PAF [14,16]. Interestingly, LY311727 showed little or
no e¡ect on chitosan-induced AA release from the unprimed
cells (Fig. 3), which is consistent with our previous ¢nding
that unprimed P388D1 cells contain low amounts of sPLA2
[15].
4. Discussion
LMW chitosan particles have previously been shown to
bind to macrophage mannose receptors, which mediate the
internalization of the chitosan particles [5]. Once inside the
macrophage, chitosan is eventually degraded by hydrolytic
enzymes present in the phagosome such as lysozyme and N-
acetyl-L-D-glucosaminidase [5]. In the current study, we dem-
onstrate that LMW chitosan particles are able to activate the
macrophages for an enhanced AA release response. Interest-
ingly, in addition to direct macrophage activation by chitosan,
our current study has led to the unexpected discovery that if
the cells are pretreated with LPS at non-stimulatory condi-
tions (100 ng/ml, 1 h pretreatment), a high level of priming
is induced. This results in an enhanced AA release response to
chitosan. Therefore, chitosan behaves in this respect much like
the pro-in£ammatory lipid mediator PAF [11^14].
Examination of the e¡ectors responsible for chitosan-in-
duced AA mobilization in unprimed and LPS-primed cells
showed again a remarkable similarity with the LPS/PAF sit-
uation [14,16], in that Group IV cPLA2 and Group V sPLA2
but not Group VI iPLA2 were found to be involved in the
response. Chitosan appears to induce AA release in the un-
primed cells by activating the Group IV cPLA2. In contrast,
in the LPS-primed cells, not only the Group IV cPLA2 but
also the Group V sPLA2 appear to be involved. This results in
an enhanced AA release response. That the sPLA2 does not
appreciably participate in the AA release response to chitosan
of the unprimed cells was not unexpected, since unprimed cells
have been found to possess little sPLA2 [15], and our previous
data have indicated that one main mechanism for the LPS to
prime the cells for an enhanced AA release involves the in-
creased expression of Group V sPLA2 [15]. As a consequence
of such an increase in sPLA2 levels in the LPS-primed cells,
the cells are now better equipped to release higher amounts of
AA in response to a subsequent chitosan stimulation.
In summary, the data presented in this study indicate that
chitosan possesses pro-in£ammatory properties similar to
those of PAF. In accordance with our data, it has recently
been reported that chitosan particles are also able to stimulate
canine neutrophils to synthesize leukotriene B4 [20].
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